Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
Name | Title | Since | Age |
|---|---|---|---|
| Brian F. Sullivan | Co-Founder, Chairman & CEO | 2012 | 64 |
| Lance G. Laing | Co-Founder, Chief Science Officer, VP, Secretary & Director | 2012 | 64 |
| Leo T. Furcht | Independent Director | 2019 | 79 |
| David F. Dalvey | Independent Director | 2014 | 68 |
| Richard J. Nigon | Independent Director | 2017 | 78 |
| Edward Greeno | Member of Scientific Advisory Board | - | - |
| Sara A. Hurvitz | Member of Scientific Advisory Board | - | - |
| Carol Lange | Member of Scientific Advisory Board | - | - |
| Benita Katzenellenbogen | Member of Scientific Advisory Board | - | - |
| Ronald C. McGlennen | Member of Scientific Advisory Board | - | - |
| John Katzenellenbogen | Member of Scientific Advisory Board | - | - |
| Mothaffar F. Rimawi | Member of Scientific Advisory Board | 2019 | - |
| Lee S. Schwartzberg | Member of Scientific Advisory Board | 2019 | - |
| Mark D. Pegram | Member of Scientific Advisory Board | - | - |
| Stanley M. Marks | Member of Scientific Advisory Board | - | 79 |
| Manfred Auer | Member of Scientific Advisory Board | - | - |
| Adam M. Brufsky | Member of Scientific Advisory Board | - | - |
| Richard E. Buller | Independent Director | 2019 | 76 |
| Bora Lim | Member of Scientific Advisory Board | 2020 | - |
| Ben Ho Park | Member of Scientific Advisory Board | 2020 | - |
| Hung Khong | Member of Scientific Advisory Board | 2021 | - |
| Alberto Montero | Member of Scientific Advisory Board | 2021 | - |
| Polly A. Murphy | Independent Director | 2022 | 61 |
| Charles R. Romp | Independent Director | 2026 | 58 |